Search results
Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 months agoEditas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript November 3, 2023 Editas...
Where Will Editas Medicine Be in 1 Year?
Motley Fool· 1 year agoGene-editing specialist Editas Medicine (NASDAQ: EDIT) fits the bill, which is why the company's shares have plunged this year. Could this be what's in...
Is Editas Medicine Stock a Buy Now?
Motley Fool· 11 months agoInvestors tend to move away from somewhat speculative stocks when the economic going gets rough. Editas Medicine's most advanced candidate is EDIT-301,...
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest...
Simply Wall St. via Yahoo Finance· 4 days agoEditas Medicine, Inc. (NASDAQ:EDIT) just released its latest quarterly report and things are not...
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool via Yahoo Finance· 4 months agoEditas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few...
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
Motley Fool via Yahoo Finance· 2 months agoShares of Editas Medicine (NASDAQ: EDIT) charged sharply higher this week, soaring as much as 41.6%,...
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Simply Wall St. via Yahoo Finance· 1 year agoWe can readily understand why investors are attracted to unprofitable companies. For example,...
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Motley Fool via Yahoo Finance· 1 week agoClinical-stage biotech Editas Medicine (NASDAQ: EDIT) delivered quarterly results that fell well...
Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 74%...
Simply Wall St. via Yahoo Finance· 1 year agoEvery investor in Editas Medicine, Inc. (NASDAQ:EDIT) should be aware of the most powerful...
Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ...
GuruFocus.com via Yahoo Finance· 6 months agoEditas Medicine Inc (NASDAQ:EDIT) reports a net loss of $45.0 million for Q3 2023, down from $55.7...